Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154745 | 1.00 | GPR119 (0.44) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6154111 | 0.91 | KDM4D (0.42) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6154113 | 0.91 | KDM4D (0.42) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6154611 | 0.91 | AAK1 (0.43) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6154071 | 0.91 | AAK1 (0.43) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6154068 | 0.91 | AAK1 (0.43) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6153458 | 0.84 | KDM4D (0.49) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6153457 | 0.84 | KDM4D (0.49) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6155283 | 0.84 | KDM4D (0.49) | GPR119KDM4DAAK1CTSKTRPA1 | |
| SCHEMBL6154623 | 0.81 | ROCK2 (0.44) | IRAK4USP30ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GPR119 279/4885KDM4D 2098/4885AAK1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.